Results 171 to 180 of about 5,770,101 (353)

The effects of perceived risk and responsibility on the acceptance of a Human Papillomavirus vaccine by college men [PDF]

, 2009
In the summer of 2006 the Food and Drug Administration approved a new vaccine to prevent four types of the Human Papillomavirus believed to cause the majority of genital warts and cervical cancer in women.
Mitiguy, Angela Marie
core   +1 more source

Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects

Advanced Science, EarlyView.
Bacterial outer membrane vesicles (OMVs) have emerged as versatile platforms for cancer vaccine development owing to their intrinsic immunostimulatory properties and high engineering flexibility. This review summarizes OMV biology, immune mechanisms, and engineering strategies that enhance vaccine efficacy, discusses key translational challenges, and ...
Jiabeini Zhang, Tianyu Shao, Fengjiang Qu, Caiyun Bai, Sijie Li, Pin Gao, Wenna Li, Keman Cheng, Xiao Zhao, Zhimin Fan   +9 more
wiley   +1 more source

A Potent and Effective Suicidal Listeria Vaccine Platform. [PDF]

, 2019
Live-attenuated Listeria monocytogenes has shown encouraging potential as an immunotherapy platform in preclinical and clinical settings. However, additional safety measures will enable application across malignant and infectious diseases.
Benanti, Erin L, Brockstedt, Dirk G, Chen, Chen, Dubensky, Thomas W, Fassò, Marcella, Hanson, William G, Lauer, Peter, Lemmens, Edward E, Leong, Meredith L, Liu, Weiqun, Portnoy, Daniel A, Rae, Chris S, Skoble, Justin   +12 more
core  

Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells

Advanced Science, EarlyView.
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin, Dingqin Cai, Chunli Jian, Yaxian Qi, Linpeng Zheng, Qiao Yang, Longyao Zhang, Diangang Chen, Lingchen Li, Ping Cai, Lingyou Sun, Luping Zhang, Jianguo Sun   +12 more
wiley   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective. [PDF]

, 1986
Kittens immunized with purified native FeLV-gp70 or -gp85 envelope proteins developed ELISA, but not virus neutralizing, antibodies in their serum to both whole FeLV and FeLV-gp70.
Birch, D, Johnson, L, Pedersen, NC, Theilen, GH   +3 more
core  

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into Tumor Editing Therapy

Pharmaceutics
Extensive research into mRNA vaccines for cancer therapy in preclinical and clinical trials has prepared the ground for the quick development of immune-specific mRNA vaccines during the COVID-19 pandemic.
Theodora Katopodi, Savvas Petanidis, Eirini Grigoriadou, Doxakis Anestakis, Charalampos Charalampidis, Ioanna Chatziprodromidou, George Floros, Panagiotis Eskitzis, Paul Zarogoulidis, Charilaos Koulouris, Christina Sevva, Konstantinos Papadopoulos, Panagiota Roulia, Stylianos Mantalovas, Marios Dagher, Alexandros Vasileios Karakousis, Nikolaos Varsamis, Konstantinos Vlassopoulos, Vasiliki Theodorou, Chrysi Maria Mystakidou, Nikolaos Iason Katsios, Konstantinos Farmakis, Christoforos Kosmidis   +22 more
doaj   +1 more source

Multi-antigen spherical nucleic acid cancer vaccines

Nature Biomedical Engineering, 2023
Michelle H. Teplensky, M. Evangelopoulos, J. Dittmar, Connor M. Forsyth, Andrew J Sinegra, Shuya Wang, C. Mirkin   +6 more
semanticscholar   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source